Gubra earns USD 50 million milestone as AbbVie starts Phase 2 trial of obesity drug ABBV-295
ABBV•AbbVie starts Phase 2 trial of ABBV-295
Gubra disclosed AbbVie has started a Phase 2 trial of obesity drug candidate ABBV-295, triggering a USD 50 million milestone payment.
Earlier Phase 1 results have already been presented, indicating weight loss potential with acceptable safety and tolerability.
The Phase 2 study will test multiple dosing approaches in adults with obesity or overweight, with efficacy readouts expected later.
ABBV-295 targets amylin, positioning it as a distinct mechanism from GLP-1 or GIP-based weight-loss drugs.
The 2025 license deal leaves Gubra eligible for up to USD 1.875 billion in milestones, plus tiered royalties on global net sales.
